Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.

Ziyi XuXuezhi HaoKe YangQi WangJing WangLin LinFei TengJun-Ling LiPuyuan Xing

Published in: Journal of cancer research and clinical oncology (2022)

ICI rechallenge may be an option for NSCLC after progress to immunotherapy. Further studies to confirm the efficacy and investigate prognostic factors are warranted.

Keyphrases

prognostic factors
small cell lung cancer
squamous cell carcinoma
case control
advanced non small cell lung cancer
brain metastases